Proteus Syndrome
4
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
3 programs1
1
MK-7075Phase 2
MK-7075Phase 1
Study of Proteus Syndrome and Related Congenital DisordersN/A
Genome & CompanyKorea - Suwon
3 programs1
1
MK-7075Phase 21 trial
MK-7075Phase 11 trial
Study of Proteus Syndrome and Related Congenital DisordersN/A1 trial
Active Trials
Sharp TherapeuticsPA - Pittsburgh
1 programARQ 092N/A1 trial
Active Trials
NCT03317366No Longer Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Genome & CompanyMK-7075
Genome & CompanyMK-7075
Genome & CompanyStudy of Proteus Syndrome and Related Congenital Disorders
Clinical Trials (4)
Total enrollment: 1,551 patients across 4 trials
MK-7075 (Miransertib) in Proteus Syndrome
Start: May 2022Est. completion: Jul 202845 patients
Phase 2Recruiting
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
Start: Nov 2015Est. completion: Jun 20226 patients
Phase 1Completed
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
N/ANo Longer Available
Study of Proteus Syndrome and Related Congenital Disorders
Start: Apr 19941,500 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 1,551 patients
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.